Capital International Investors Trims Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Capital International Investors cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 62.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 479,106 shares of the biotechnology company’s stock after selling 798,454 shares during the quarter. Capital International Investors owned 0.39% of Arrowhead Pharmaceuticals worth $13,702,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in ARWR. Washington Trust Advisors Inc. acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $25,000. Neo Ivy Capital Management acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth approximately $41,000. Quest Partners LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth approximately $45,000. Friedenthal Financial bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $51,000. Finally, Headlands Technologies LLC grew its position in Arrowhead Pharmaceuticals by 7,696.8% in the first quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock valued at $69,000 after acquiring an additional 2,386 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research note on Thursday, June 20th. The Goldman Sachs Group initiated coverage on Arrowhead Pharmaceuticals in a research note on Wednesday, June 5th. They issued a “neutral” rating and a $31.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a report on Tuesday, July 16th. Finally, Morgan Stanley decreased their price target on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating on the stock in a research note on Monday, May 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $43.25.

Insider Activity

In related news, Director Victoria Vakiener sold 1,799 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total value of $41,934.69. Following the transaction, the director now directly owns 30,205 shares of the company’s stock, valued at approximately $704,078.55. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the completion of the transaction, the director now directly owns 30,205 shares of the company’s stock, valued at $704,078.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tracie Oliver sold 9,394 shares of the business’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $25.28, for a total transaction of $237,480.32. Following the sale, the insider now directly owns 127,107 shares of the company’s stock, valued at $3,213,264.96. The disclosure for this sale can be found here. Insiders own 4.50% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 2.6 %

Shares of NASDAQ:ARWR traded down $0.75 on Friday, reaching $28.19. 847,114 shares of the company traded hands, compared to its average volume of 1,280,164. The business’s 50-day simple moving average is $25.87 and its 200 day simple moving average is $27.90. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $20.67 and a 52 week high of $39.83. The stock has a market capitalization of $3.50 billion, a P/E ratio of -6.63 and a beta of 0.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. During the same period in the prior year, the firm earned $0.45 EPS. The business’s revenue was down 100.0% on a year-over-year basis. Sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.04 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.